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History of  Present Illness: The patient presented to the derma-
tology clinic complaining of a mass extending from the back of his neck. Associ-
ated symptoms included headaches, pain upon lying down and sleeping, as well 
as inability to keep proper hygiene of the area involved. The physical disfigurement 
significantly affected the patient’s quality of life. He reported a prior surgical 
 excision at the site in childhood. Overtime the lesion recurred, enlarging in size 
gradually in a span of  15-20 years. Multiple other neurofibromas were excised in 
the past, particularly one on his left flank and his right shoulder. Unfortunately the 
patient died of cardio- pulmonary causes in late February.
Medical History/Surgical History: NF1, left Horner syndrome, 
COPD, sleep apnea, GERD, DM II, adenocarcinoma of the colon, C2-C4 laminec-
tomy with fusion using left ilial bone graft as a child, left inguinal herniorrhaphy, 
multiple neurofibromas excised as per patient
Family History: NF1 in his father, brother, sister, aunts and uncles. He 
has 2 sisters who are not affected. Work up of his two daughters is in progress.
Medications: Gabapentin, mirtazapine, diclofenac, glucophage, omepra-
zole, montelukast, ipratropium inhaler, salbutamol inhaler, fluticasone propionate 
nasal spray
Previous Treatments: Surgical excisions
Physical Examination: Overhanging from the posterior neck a 
 tender mass with overgrowth of epidermal and subcutaneous tissue associated 
with a wrinkled and “peau d’orange” texture. Another diffuse, thick and irregular 
tumor is noted on the right shoulder. Multiple flesh-toned, pink and tan polypoid, 
soft, rubbery nodules varying in size scattered throughout the trunk and 
 extremities. Axillary freckling is present.
Studies: Cervical spine MRI, April 2007: 
“7.1x2.3x2.8 cm plexiform neurofibroma arising from 
the roots and trunks of the right brachial plexus. Right 
C2-C3 through  C6-C7 neural foraminal neurofibromas 
or schwannomas, the largest of which measures 
 approximately 1.7 cm at  C4-C5. Small nerve sheath 
 tumor of the adipose tissues  inferior to the left occipital 
bone”. Cervical spine MRI in September 2010 showed 
“no interval change involving the right brachial plexus 
neurofibroma but did reveal  enlargement of exiting 
nerve roots bilaterally, more on the right side without a discrete mass.”
Reason for Presentation: Interest
Discussion: Plexiform neurofibroma (PN) is a benign peripheral nerve 
sheath tumor, con sidered to be pathognomonic of neurofibromatosis type 1 (NF1). 
It is seen in about 15-30% of individuals with NF1, typically presenting at birth or 
becoming physically apparent within the first 2-5 years of life. PN  clinically fea-
tures a  diffuse large, bag-like mass, often with overlying hyperpigmentation or 
hyper trichosis. The tumors can be severely disfiguring and locally invasive, most 
 commonly involving the trigeminal or upper  cervical nerves. 
Histopathologically, PNs are similar to discrete neurofibromas: a myxomatous, 
 hypocellular background with spindle cells, mast cells, fibroblasts and vascular 
components arranged in closely packed multiple fascicles. The tumor is intra-
neural and each part of the plexus is confined by a thickened perineurium.
The natural progression of PN is poorly understood. Certain lesions remain 
 quiescent for a long time, whereas others may grow aggressively, especially 
 during childhood and adolescence. Rarely, rapid growth or pain can be suggestive 
of  malignant transformation. With a lifetime risk of 8-13%,  malignant peripheral 
nerve sheath tumors (MPNSTs) are not uncommon in NF1 and are one of the 
leading causes of premature death. They carry a poor prognosis with a 5-year 
survival of only 21-41%. 
There is increasing evidence that mutations in genes other than the NF1 gene 
contribute to the development of malignancies. Studies have shown that inac-
tivation of the p53  tumor suppressor gene, upregulation of the CD44 adhesion 
 molecule and decreased or lost PTEN expression accom panies MPNST formation.
The management of patients with PN is not well defined and is aimed mostly at 
controlling symptoms. Surgical approach is difficult, as it produces poor results 
with a high rate of re-growth and potential risk for long-term neurologic sequelae. 
Routine MRI scans may be of value in monitoring patients with rapidly growing 
tumors.
A novel therapeutic option has emerged as a result of recent research in PN 
pathogenesis. A mouse model study concluded that tumor formation is driven 
by NF1 heterozygosity in marrow, particularly the mast cells expressing high-
functioning c-kit receptors. Genetic inhibition of c-kit protects against  tumorigenic 
 potential, further confirming these findings. As such, imatinib mesylate (Gleevec), 
a potent inhibitor of c-kit receptor tyrosine kinase, successfully reduced existing 
PN volume in a mouse model. A case report of a critically ill three-year-old girl 
with a PN compressing her airway had a 75% volume reduction of her tumor with 
imatinib administration. Imatinib for PN management is now a phase II  clinical 
 trial in its final stages.
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Figure 1: Overhanging from the posterior 
neck is a tender mass with overgrowth of 
epidermal and subcutaneous tissues. Also 
multiple flesh-toned, pink and tan polyp-
oid, soft, rubbery nodules varying in size 
scattered throughout back.
Figure 2: Side view of the overhanging 
bag-like mass.
Figure 3: Another diffuse, thick and irreg-
ular tumor is noted on the right shoulder.
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